Cargando…
Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
(1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were scree...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299195/ https://www.ncbi.nlm.nih.gov/pubmed/37373705 http://dx.doi.org/10.3390/jcm12124010 |
_version_ | 1785064303740583936 |
---|---|
author | Frustaci, Andrea Galea, Nicola Dominici, Lorenzo Verardo, Romina Alfarano, Maria Scialla, Rossella Richetta, Antonio Giovanni |
author_facet | Frustaci, Andrea Galea, Nicola Dominici, Lorenzo Verardo, Romina Alfarano, Maria Scialla, Rossella Richetta, Antonio Giovanni |
author_sort | Frustaci, Andrea |
collection | PubMed |
description | (1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were screened for cardiac involvement. Among them, five male patients (aged 56 ± 9.5 years) with a moderate–severe form of PS showed dilated cardiomyopathy (LVEF < 35%) with normal coronary arteries and valves. They underwent a left-ventricular endomyocardial biopsy for evaluation of myocardial substrate. Endomyocardial samples were processed for histology and immunohistochemistry, including myocardial expression of Toll-Like Receptor 4 (TLR4) and interleukin-17A (IL-17A), which play a major role in PS pathogenesis. Real-time PCRs were carried out for cardiotropic viruses, and Western blot analysis was conducted for myocardial expression of IL-17A. Patients’ sera were tested for anti-heart autoantibodies. Active lymphocytic myocarditis was revealed in all five patients, characterized by an absence of viral genomes with PCR, positive anti-heart autoantibodies, overexpression of TLR-4 and enhancement of IL-17-A during western blot analysis, showing a 2.48-fold increase in psoriatic myocarditis compared with no psoriatic myocarditis and a six-fold increase compared to myocardial controls. Treatment included combination of prednisone (1 mg/kg daily for 4 weeks, tapered to 0.33 mg/kg) and azathioprine (2 mg/kg, daily) in 3 pts or secukinumab (SK, 150 mg/weekly for 4 weeks followed by 150 mg/monthly) in 2 pts for 6 months. LVEDD and LVEF improved in the first 3 pts (−14% and + 118%, respectively), while they completely recovered (LVEF > 50%) in the last 2 pts on SK. (4) Conclusions: IL-17A-related myocarditis can occur in up to 5% of patients with PS. It manifests as progressive dilated cardiomyopathy. It may completely recover following SK administration. |
format | Online Article Text |
id | pubmed-10299195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102991952023-06-28 Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration Frustaci, Andrea Galea, Nicola Dominici, Lorenzo Verardo, Romina Alfarano, Maria Scialla, Rossella Richetta, Antonio Giovanni J Clin Med Article (1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were screened for cardiac involvement. Among them, five male patients (aged 56 ± 9.5 years) with a moderate–severe form of PS showed dilated cardiomyopathy (LVEF < 35%) with normal coronary arteries and valves. They underwent a left-ventricular endomyocardial biopsy for evaluation of myocardial substrate. Endomyocardial samples were processed for histology and immunohistochemistry, including myocardial expression of Toll-Like Receptor 4 (TLR4) and interleukin-17A (IL-17A), which play a major role in PS pathogenesis. Real-time PCRs were carried out for cardiotropic viruses, and Western blot analysis was conducted for myocardial expression of IL-17A. Patients’ sera were tested for anti-heart autoantibodies. Active lymphocytic myocarditis was revealed in all five patients, characterized by an absence of viral genomes with PCR, positive anti-heart autoantibodies, overexpression of TLR-4 and enhancement of IL-17-A during western blot analysis, showing a 2.48-fold increase in psoriatic myocarditis compared with no psoriatic myocarditis and a six-fold increase compared to myocardial controls. Treatment included combination of prednisone (1 mg/kg daily for 4 weeks, tapered to 0.33 mg/kg) and azathioprine (2 mg/kg, daily) in 3 pts or secukinumab (SK, 150 mg/weekly for 4 weeks followed by 150 mg/monthly) in 2 pts for 6 months. LVEDD and LVEF improved in the first 3 pts (−14% and + 118%, respectively), while they completely recovered (LVEF > 50%) in the last 2 pts on SK. (4) Conclusions: IL-17A-related myocarditis can occur in up to 5% of patients with PS. It manifests as progressive dilated cardiomyopathy. It may completely recover following SK administration. MDPI 2023-06-12 /pmc/articles/PMC10299195/ /pubmed/37373705 http://dx.doi.org/10.3390/jcm12124010 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frustaci, Andrea Galea, Nicola Dominici, Lorenzo Verardo, Romina Alfarano, Maria Scialla, Rossella Richetta, Antonio Giovanni Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title | Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title_full | Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title_fullStr | Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title_full_unstemmed | Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title_short | Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration |
title_sort | interleukin-17a-correlated myocarditis in patients with psoriasis: cardiac recovery following secukinumab administration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299195/ https://www.ncbi.nlm.nih.gov/pubmed/37373705 http://dx.doi.org/10.3390/jcm12124010 |
work_keys_str_mv | AT frustaciandrea interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT galeanicola interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT dominicilorenzo interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT verardoromina interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT alfaranomaria interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT sciallarossella interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration AT richettaantoniogiovanni interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration |